Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CONTINUING ACCESS TO THE TYROSINE KINASE INHIBITOR OF VEGFR-2, AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 IN CLINICAL TRIALS

NCT00828919 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00828919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00828919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CONTINUING ACCESS TO THE TYROSINE KINASE INHIBITOR OF VEGFR-2, AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 IN CLINICAL TRIALS
Lead sponsor
Pfizer
Phase
Not applicable
Overall status
Completed
Start date
March 7, 2003
Completion date
August 14, 2023
Enrollment
52 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors